In compliance with current regulations, let us know which audience you belong to:
Various frequencies.
Endless possibilities.
LM® LLLT is our patented photobiomodulation technology—it works by triggering endogenous heating, stimulating ATP production in both ophthalmological and dermatological applications.
This innovative approach ensures effective and versatile outcomes, whether addressing anterior and posterior segment conditions in ophthalmology or catering to broader applications in dermatology.
Light Modulation® Low-level Light Therapy can be leveraged employing different light frequencies—each with its own unique benefits and use cases.
Used for Inflammation Reduction and ATP Production Stimulus.
Used for Bacteria Elimination, Microbiome Stabilization
Used for Drainage and Swelling Reduction
The Yellow light (590 nm wavelength) naturally inhibits expression of vascular endothelial growth factor (VEGF), a signaling protein that stimulates the formation of blood vessels that contributes to the development of the wet-form of AMD.
It also increases the signaling protein, nitric oxide which reduces oxidative stress-mediated injury in the cell and increases local O2 delivery. Light absorption leads to NO dissociation from CCO, restoring mitochondrial function and increasing ATP production.
> Oxydative Stress Reduction
> VEGF Inhibition
> Oedema Reduction & Drainage
The Red (630 nm) light exposure is directly associated with a significant increase in ATP. The 630 nm wavelength is chosen based on its known interaction with cellular photo acceptors in CCO.
The 630 nm wavelength promote electron transfer and oxygen binding, respectively, in CCO leading to restoration of mitochondria function and increases in metabolic activity (i.e. energy production) and inhibition in inflammatory events and cells death.
> HIF-1α-Factor Stimulus
> Inflammatory Biomarkers Reduction
> ATP Stimulus
* Available only for Dermatological Use
STONECIPHER, Karl, et al. Combined low level light therapy and intense pulsed light therapy for the treatment of meibomian gland dysfunction. Clinical Ophthalmology, 2019
And consequently, the treatment improved by 10 points or more the patient’s ocular surface disease index—i.e., OSDI Index, in over 70% of cases, with only one treatment.
Recently run thermography studies have shown upper and lower meibomian glands being simultaneously, directly treated at optimal temperature—i.e., 42°C, through LM® LLLT.
Light Modulation® LLLT triggers endogenous heating to both eyelids, stimulating ATP production and removing blockage from meibomian glands preventing proper functioning—and it does so with zero discomfort for the patient.